Answers are grounded in this paper and cite their sources.
R EQUIREMENTS for establishing a dose individual-ization program for an immunosuppressant based on measurement of active drug concentration include availability of a validated analysis method; pharmacokinetic characterization of the drug; identification and characterization of drug metabolites; concentration-clinical response relationship information for active drug; a sampling time; and dosage adjustment strategy.Such suggested requirements are now available for mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF).The following is a summary of the essential features of the suggested requirements and a description of an ongoing prospective investigation of a therapeutic drug monitoring strategy for MPA in renal transplant patients.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: